In the rapidly evolving landscape of the pharmaceutical industry, the demand for integrated solutions, from formulation development to GMP manufacturing, is on the rise. Companies are seeking partners who can provide fit-for-purpose services to meet the growing challenges of manufacturing super and complex generics.
The market for contract development and manufacturing organizations (CDMOs) is expected to double by 2034, driven by factors such as growing R&D activities, personalized medicines, and the production of biologics. Resilience is a key factor in the industry, as highlighted in recent publications discussing how CDMOs are enhancing supply chain resilience through outsourcing formulation development and manufacturing. With the expansion of facilities and services, CDMOs are well-positioned to support innovators in early-phase product development and the manufacturing of advanced dosage forms.
Read more from search.yahoo.com
You might also like to read: Succeeding Under Decay: How Radiopharma CDMOs Thrive – And Why Others Don’t